CyclophosphamideAntineoplastic AgentsRadiation DosageRadiation, IonizingDoxorubicinRadiation InjuriesAntineoplastic Combined Chemotherapy ProtocolsVincristineAntineoplastic Agents, AlkylatingDose-Response Relationship, RadiationRadiation TolerancePhosphoramide MustardsRadiationDrug Screening Assays, AntitumorCell Line, TumorNeoplasmsEtoposideRadiation ProtectionCombined Modality TherapyRadiation MonitoringPrednisoneCisplatinBreast NeoplasmsMethotrexateFluorouracilDrug Resistance, NeoplasmApoptosisTreatment OutcomeImmunosuppressive AgentsDose-Response Relationship, DrugDrug Administration ScheduleAntineoplastic Agents, PhytogenicCell SurvivalAntibiotics, AntineoplasticEpirubicinPulse Therapy, DrugRadiation OncologyPaclitaxelTime FactorsThiotepaRadiation Injuries, ExperimentalBusulfanGamma RaysTumor Cells, CulturedWhole-Body IrradiationDisease-Free SurvivalXenograft Model Antitumor AssaysCosmic RadiationPrednisoloneDrug Delivery SystemsRemission InductionMice, NudeDNA DamageRadiotherapyMitoxantroneAntibodies, Monoclonal, Murine-DerivedLymphoma, Non-HodgkinBleomycinRadiation PneumonitisLeukopeniaDrug CarriersSurvival AnalysisNeoplasms, Radiation-InducedBone Marrow TransplantationVidarabineRadiotherapy DosageDrug SynergismProdrugsChemotherapy, AdjuvantCell ProliferationChlorambucilGranulocyte Colony-Stimulating FactorRadiation-Sensitizing AgentsCarmustineSurvival RateMelphalanNeoplasm Transplantation